Brief: Galmed Announces Results From First-In-Man Pharmacokinetics Study Of Oral Formulation Of Aramchol Meglumine (Am) 400Mg Am Increases Bioavailability By ~500% In Comparison To Aramchol Free Acid (Aa) 300Mg

Eocene

14/05/2026 12:34

May 14 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O:

GALMED ANNOUNCES RESULTS FROM FIRST-IN-MAN PHARMACOKINETICS STUDY OF ORAL FORMULATION OF ARAMCHOL MEGLUMINE (AM); 400MG AM INCREASES BIOAVAILABILITY BY ~500% IN COMPARISON TO ARAMCHOL FREE ACID (AA) 300MG

Source text: ID:nPn7kfxd2a

Further company coverage: GLMD.O

 ((Reuters.Briefs@thomsonreuters.com;))